Down -30.2% in 4 Weeks, Here's Why MaxCyte (MXCT) Looks Ripe for a Turnaround [Yahoo! Finance]
MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market, Very Low Share Price [Seeking Alpha]
MaxCyte, Inc. (NASDAQ: MXCT) was given a new $6.00 price target on by analysts at BTIG Research. They now have a "buy" rating on the stock.
MaxCyte, Inc. (NASDAQ: MXCT) had its price target lowered by analysts at Stifel Nicolaus from $11.00 to $9.00. They now have a "buy" rating on the stock.
MaxCyte, Inc. (MXCT) Q4 2024 Earnings Call Transcript [Seeking Alpha]